Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Blood Cancer Treatment Market Outlook

The blood cancer treatment market size is projected to be valued at US$ 5,935.9 million in 2023 and is expected to rise to US$ 15,735.3 million by 2033. The sales of blood cancer treatment are projected to thrive at a significant CAGR of 10.2% during the forecast period.

Growth is attributed to the increasing involvement of key and prominent companies in the research and development of blood cancer (leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma) treatment across the globe.

Blood cancer (leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma) is a general term used for the cancers that affect the blood, bone marrow, or lymphatic system. Most of these cancers start in the bone marrow where blood cells (RBC, WBC, and platelets) are produced from bone marrow stem cells.

In cancerous conditions, the differentiation of bone marrow stem cells is interrupted to produce abnormal blood cells which hamper the normal functioning of the blood. There are 4 types of blood cancer such as leukemia, Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), and multiple myeloma. Factors that are expected to augment the blood cancer treatment market growth in the forthcoming years are:

  • Increasing government initiatives for cancer awareness.
  • The rising prevalence of cancer worldwide.
  • Strong research and development initiatives from key players.
  • The increasing demand for personalized medicine.

Strong costs attributed to certain therapeutics in the blood cancer treatment market are one of the key factors that are expected to hamper the market growth in certain emerging regions over the analysis period.

Attributes Details
Blood Cancer Treatment Market Estimated Size (2023) US$ 5,935.9 million
Blood Cancer Treatment Market CAGR (2023 to 2033) 10.2%
Blood Cancer Treatment Market Forecasted Size (2033) US$ 15,735.3 million

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Which are the Prominent Drivers Spearheading Blood Cancer (Leukemia, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, and Multiple Myeloma) Treatment Market Growth?

The high incidence rate of blood cancers in the United States of America (leukemia-13.0, NHL-19.8, HL-2.7, myeloma-6.7 cases per 100,000 population in 2014) is one of the leading factors for the growth of the blood cancer treatment market in the United States. In addition, advancements in technology, personalized medicine, and cost-effective treatment procedures are a few other factors that are expected to fuel the growth of the global blood cancer treatment market during the forecast period.

The increasing involvement of key and prominent companies in research and development is leading to strong pipeline candidates, which is another factor that is anticipated to boost the growth of the blood cancer treatment market over the analysis period.

Many biopharmaceutical market players like Spectrum Pharmaceuticals and Amgen, are showing an increasing interest in the development of new products. Also, this increasing interest in treatment products is due to the increasing number of individuals suffering from blood cancer. For instance,

Kura Oncology is conducting a clinical trial for a pipeline candidate called tipifarnib for the disease indication of peripheral T-cell lymphoma. Currently, the clinical trial is in Phase II and received the fast-track designation from the FDA in March 2020. This factor is anticipated to further drive the growth of the blood cancer treatment market during the forecast period.

What are the Challenges Faced by The Blood Cancer Treatment Industry?

The divergent nature of blood cancers and increasing stringency in the regulatory requirements are some of the significant factors that are expected to impede the growth of the blood cancer treatment market over the analysis period.

There are firm factors that are restraining the adoption of therapeutics used in blood cancer treatment. The significant limiting factor restraining the growth includes the lower lymphoma treatment rates in emerging countries. This is attributed to the high costs of therapies. This results in a limited number of individuals undergoing this treatment, and a large number of these patients are not able to afford treatments such as immunotherapies.

Most of the time, the cost of such products is not accessible and affordable to poor patients. In addition, the unavailability of suitable payment plans for the treatment of these diseases is another key factor that is anticipated to hinder market growth in the forthcoming years.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Comparative View of the Blood Cancer Treatment Market

Blood Cancer Treatment Market:

Attributes Blood Cancer Treatment Market
CAGR (2023 to 2033) 10.2%
Market Value (2033) US$ 15,735.3 million
Growth Factor Growth is attributed to the increasing involvement of key and prominent companies in the research and development of blood cancer treatment across the globe.
Opportunity The increasing involvement of key and prominent companies in research and development is leading to strong pipeline candidates, which is another factor that is anticipated to boost the growth of the blood cancer treatment market over the analysis period.
Key Trends Factors such as increasing government initiatives for cancer awareness, the rising prevalence of cancer worldwide, and strong research and development initiatives from key players.

Stem Blood Cancer Treatment Market:

Attributes Stem Blood Cancer Treatment Market
CAGR (2023 to 2033) 9.6%
Market Value (2033) US$ 730 million
Growth Factor Creating cutting-edge genetic techniques for stem cell analysis and raising public understanding of the relevance of regenerative medicine in the treatment of disease.
Opportunity Players in the market have a lot of room to grow owing to low regulatory obstacles for conducting stem cell-based investigations and a business-friendly climate in developing nations.
Key Trends China, India, and Brazil are just a few of the emerging markets that manufacturers and distributors of stem blood cancer treatment have discovered to be desirable locations.

Blood Cancer Treatment Market:

Attributes Blood Cancer Treatment Market
CAGR (2023 to 2033) 4.9%
Market Value (2033) US$ 434.0 million
Growth Factor The increasing geriatric population is leading to a rise in hip injuries and this is promoting the blood cancer treatment market during the forecast period.
Opportunity The blood cancer treatment market opportunities might surge owing to a great number of research and development activities for developing novel drugs.
Key Trends The demand for blood cancer treatment is said to escalate due to rising awareness about non-invasive methods of Blood Cancer treatment.

Category-wise Insights of Blood Cancer Treatment

Targeted Therapy Plays a Significant Role in the Treatment of Blood Cancers, Holding a Notable Share of 40.0% of the Overall Market.

By specifically targeting molecular abnormalities and genetic mutations involved in the growth and progression of cancer cells, targeted therapy offers a precise and effective approach compared to traditional chemotherapy. This approach has gained prominence in the blood cancer treatment market due to its ability to provide high response rates and improved survival outcomes for patients.

Healthcare professionals can identify specific molecular targets in individual patients, allowing for personalized treatment strategies with advancements in genetic profiling and molecular diagnostics. Further, ongoing research and clinical trials continue to expand the applications of targeted therapy, leading to the development of novel agents and combination approaches.

Hospitals have a Prominent Share of 36.90% in the Blood Cancer Treatment Market.

Blood cancer is a complex condition that requires specialized medical care, including diagnosis, treatment, and follow-up monitoring. Hospitals play a crucial role in providing comprehensive healthcare services to patients with blood cancer.

Hospitals provide a range of treatment options for blood cancer, depending on the stage and severity of the disease. These treatments may include conservative measures such as pain management, physical therapy, and lifestyle modifications. In many advanced cases, surgical interventions, such as joint-preserving procedures or joint replacement surgeries, may be performed.

Hospitals serve as centers for research and innovation in blood cancer treatment. They contribute to the development of new treatment modalities, clinical trials, and advancements in surgical techniques aimed at improving patient outcomes.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Regional Analysis of the Blood Cancer Treatment Market

Why Is North America Emerging as An Opportunistic Blood Cancer Treatment Market?

In terms of regional platforms, North America holds a significant market share in the blood cancer treatment market. The region is expected to accumulate a 38.2% market share in 2022. Further, there has been a tremendous increase in cell-based research activities over the past decade.

Increasing research in the field of regenerative medicine for the treatment of leukemia and growing awareness of personalized medicine have also resulted in the growth of this market. In addition to it, the growth in this market is driven by the high prevalence and incidence of leukemia and the rising geriatric population. According to the Leukemia & Lymphoma Society, an estimated 381,774 people are living with or in remission from leukemia in the United States of America.

The government of Canada is taking various initiatives to support leukemia research and develop novel immunotherapies. For instance,

  • In January 2016, the government of Canada announced the provision of US$ 20 million to the Centre for Commercialization of Regenerative Medicine (CCRM) to help establish a stem cell therapy development facility in Toronto (Canada).

How Is Europe Contributing to the Growth of the Blood Cancer Treatment Market?

According to Future Market Insights, Europe is expected to hold a significant growth opportunity for blood cancer treatment and reached a share of 28.7% in 2022. The second most dominant market is expected to be Europe in the forecast period, and the reasons for the region’s high share include the high number of individuals requiring treatment arising from the region and also the high usage of advanced therapeutics.

A few more factors that are expected to escalate the growth of the blood cancer treatment market during the forecast period are:

  • The high prevalence of lymphoma.
  • The great awareness among the patient population for lymphoma treatment.
  • The high rate of adoption of advanced lymphoma therapeutic drugs.
  • The great healthcare expenditure of the region.

Constant research and development by key market players in the form of clinical trials for new drug candidates for lymphoma treatment have also boosted the market in the region.

Where Does Asia Pacific Region Stand in The Blood Cancer Treatment Market?

According to Future Market Insights, Asia-Pacific is expected to grow with significant growth opportunities for the blood cancer treatment market which accounted for a significant share of 24.2% in 2022. Further, the key reasons for the region’s growth which together are estimated to drive the market growth during the forecast period include:

  • The approvals of key drugs such as Kymriah (tisagenlecleucel) in Japan for lymphoma treatment.
  • The under-tapped market potential of the region.
  • The existence of a large potential patient population requiring treatment.

The blood cancer (leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma) treatment market in the region is predicted to experience growth in the future due to increasing demand for lymphoma therapeutic products and increasing burden of various forms of lymphoma during the forecast period,

How is the Middle East & Africa Contributing to the Growth of the Blood Cancer Treatment Market?

According to Future Market Insights, the Middle East & Africa are expected to provide significant growth opportunities for the blood cancer treatment market and reached a share of 12.8% in 2022.

The strong economic growth prospects in the region are one of the key factors that are expected to propel the growth of the blood cancer treatment market over the analysis period. Moreover, the market is expected to develop in the future due to increasing healthcare expenditure and rising demand for advanced therapeutics by the patient population for this treatment in the region.

Competitive Landscape

Some of the key participants present in the global blood cancer treatment market are:

  • Novartis Pharmaceuticals
  • Merck & Co. Inc.
  • Bristol-Myers Squibb Company
  • AbbVie Inc.
  • Johnson & Johnson Pvt. Ltd.
  • Celgene Corporation
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Co. Ltd.

Attributed to the presence of such a high number of participants, the market is highly competitive. While global players such as Takeda Pharmaceutical Company Limited, AstraZeneca, Bayer AG, and Novartis AG, account for a considerable market size, several regional-level players are also there operating across key growth regions, particularly in North America.

Recent Developments

  • In June 2021, Bayer announced that the company had submitted the supplemental new drug application (sNDA) to the USA Food and Drug Administration (FDA). The company had also applied to marketing authorization application (MAA) to the European Medicines Agency (EMA) for the oncology treatment combination of copanlisib and rituximab in the United States of America.
  • In 2021, Novartis announced strong data from the analysis of the pivotal Phase II ELARA trial of Kymriah in patients with relapsed or refractory follicular lymphoma, with one-time Kymriah infusion, which showed an analysis of the ELARA trial demonstrated a 66% complete response rate and 86% overall response rate.
  • In February 2021, Bristol Myers Squibb announced that the company received approval for cancer immunotherapy from the USA Food and Drug Administration (FDA) for certain lymphomas. Further, the FDA approved the therapy as a treatment for adults who have certain types of non-Hodgkin lymphoma.

Scope of the Report

Attributes Details
Growth Rate CAGR of 10.2% from 2023 to 2033
Base Year of Estimation 2023
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US$ billion and Volume in Units and F-CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, growth factors, Trends, and Pricing Analysis
Key Segments Covered
  • Application
  • End User
  • By Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • The Middle East & Africa
  • Oceania
Key Countries Profiled
  • The United States
  • Canada
  • Brazil
  • Mexico
  • Germany
  • Italy
  • France
  • The United Kingdom
  • Spain
  • Russia
  • China
  • Japan
  • India
  • GCC Countries
  • Australia
Key Companies Profiled
  • Novartis Pharmaceuticals
  • Merck & Co. Inc.
  • Bristol-Myers Squibb Company
  • AbbVie Inc.
  • Johnson & Johnson Pvt. Ltd.
  • Celgene Corporation
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Co. Ltd.
Customization & Pricing Available upon Request

Key Segments Covered in the Blood Cancer Treatment Market Report

By Application:

  • for Biological/Immunotherapy Applications
  • for Chemotherapy
  • for Radiation Therapy
  • for Targeted Therapy
  • for Stem Cell Transplantation

By End User:

  • in Hospitals
  • in Clinics
  • in Cancer Rehabilitation Centers

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • Asia Pacific Excluding Japan (APEJ)
  • Japan
  • The Middle East & Africa (MEA)

Frequently Asked Questions

Which industry is the key consumer of Blood Cancer Treatment?

The healthcare industry is the primary consumer of blood cancer treatment.

How much can the Blood Cancer Treatment Market grow by 2033 in the healthcare industry?

The healthcare industry is poised to stay attractive, projecting a US$ 15 billion market by 2033.

What is the current valuation of the Blood Cancer Treatment Market?

The market is estimated to secure a valuation of US$ 5.9 billion in 2023.

Which end-use industry holds lucrative opportunities in the blood cancer treatment market?

The oncology sector holds high revenue potential in the blood cancer treatment market.

Who are the Blood Cancer Treatment Market Players?

The key players in the Blood Cancer Treatment Market are Novartis Pharmaceuticals, Merck & Co. Inc., Bristol-Myers Squibb Company, AbbVie Inc., and Johnson & Johnson Pvt. Ltd.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Application, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2023 to 2033

        5.3.1. Biological/Immunotherapy Applications

        5.3.2. Chemotherapy

        5.3.3. Radiation Therapy

        5.3.4. Targeted Therapy

        5.3.5. Stem Cell Transplantation

    5.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033

        6.3.1. Hospitals

        6.3.2. Clinics

        6.3.3. Cancer Rehabilitation Centers

    6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Western Europe

        7.3.4. Eastern Europe

        7.3.5. South Asia and Pacific

        7.3.6. East Asia

        7.3.7. Middle East and Africa

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        8.2.1. By Country

            8.2.1.1. USA

            8.2.1.2. Canada

        8.2.2. By Application

        8.2.3. By End User

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Application

        8.3.3. By End User

    8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Application

        9.2.3. By End User

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Application

        9.3.3. By End User

    9.4. Key Takeaways

10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. UK

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Western Europe

        10.2.2. By Application

        10.2.3. By End User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Application

        10.3.3. By End User

    10.4. Key Takeaways

11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Poland

            11.2.1.2. Russia

            11.2.1.3. Czech Republic

            11.2.1.4. Romania

            11.2.1.5. Rest of Eastern Europe

        11.2.2. By Application

        11.2.3. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Application

        11.3.3. By End User

    11.4. Key Takeaways

12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Bangladesh

            12.2.1.3. Australia

            12.2.1.4. New Zealand

            12.2.1.5. Rest of South Asia and Pacific

        12.2.2. By Application

        12.2.3. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Application

        12.3.3. By End User

    12.4. Key Takeaways

13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Application

        13.2.3. By End User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Application

        13.3.3. By End User

    13.4. Key Takeaways

14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of MEA

        14.2.2. By Application

        14.2.3. By End User

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Application

        14.3.3. By End User

    14.4. Key Takeaways

15. Key Countries Market Analysis

    15.1. USA

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2022

            15.1.2.1. By Application

            15.1.2.2. By End User

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2022

            15.2.2.1. By Application

            15.2.2.2. By End User

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2022

            15.3.2.1. By Application

            15.3.2.2. By End User

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2022

            15.4.2.1. By Application

            15.4.2.2. By End User

    15.5. Germany

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2022

            15.5.2.1. By Application

            15.5.2.2. By End User

    15.6. UK

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2022

            15.6.2.1. By Application

            15.6.2.2. By End User

    15.7. France

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2022

            15.7.2.1. By Application

            15.7.2.2. By End User

    15.8. Spain

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2022

            15.8.2.1. By Application

            15.8.2.2. By End User

    15.9. Italy

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2022

            15.9.2.1. By Application

            15.9.2.2. By End User

    15.10. Poland

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2022

            15.10.2.1. By Application

            15.10.2.2. By End User

    15.11. Russia

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2022

            15.11.2.1. By Application

            15.11.2.2. By End User

    15.12. Czech Republic

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2022

            15.12.2.1. By Application

            15.12.2.2. By End User

    15.13. Romania

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2022

            15.13.2.1. By Application

            15.13.2.2. By End User

    15.14. India

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2022

            15.14.2.1. By Application

            15.14.2.2. By End User

    15.15. Bangladesh

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2022

            15.15.2.1. By Application

            15.15.2.2. By End User

    15.16. Australia

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2022

            15.16.2.1. By Application

            15.16.2.2. By End User

    15.17. New Zealand

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2022

            15.17.2.1. By Application

            15.17.2.2. By End User

    15.18. China

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2022

            15.18.2.1. By Application

            15.18.2.2. By End User

    15.19. Japan

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2022

            15.19.2.1. By Application

            15.19.2.2. By End User

    15.20. South Korea

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2022

            15.20.2.1. By Application

            15.20.2.2. By End User

    15.21. GCC Countries

        15.21.1. Pricing Analysis

        15.21.2. Market Share Analysis, 2022

            15.21.2.1. By Application

            15.21.2.2. By End User

    15.22. South Africa

        15.22.1. Pricing Analysis

        15.22.2. Market Share Analysis, 2022

            15.22.2.1. By Application

            15.22.2.2. By End User

    15.23. Israel

        15.23.1. Pricing Analysis

        15.23.2. Market Share Analysis, 2022

            15.23.2.1. By Application

            15.23.2.2. By End User

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Application

        16.3.3. By End User

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. Novartis Pharmaceuticals

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

        17.1.2. Merck & Co. Inc.

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

        17.1.3. Bristol-Myers Squibb Company

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

        17.1.4. AbbVie Inc.

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

        17.1.5. Johnson & Johnson Pvt. Ltd.

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

        17.1.6. Celgene Corporation

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

        17.1.7. Amgen Inc.

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

        17.1.8. Teva Pharmaceutical Industries Ltd.

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

        17.1.9. Bayer AG

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

        17.1.10. Pfizer Inc.

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

        17.1.11. Takeda Pharmaceutical Co. Ltd.

            17.1.11.1. Overview

            17.1.11.2. Product Portfolio

            17.1.11.3. Profitability by Market Segments

            17.1.11.4. Sales Footprint

            17.1.11.5. Strategy Overview

                17.1.11.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Recommendations

Healthcare

Cancer Diagnostics Market

Published : August 2023

Healthcare

Advanced Cancer Pain Management Market

Published : February 2023

Explore Healthcare Insights

View Reports

Blood Cancer Treatment Market